1. Home
  2. NKGN vs APLM Comparison

NKGN vs APLM Comparison

Compare NKGN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NKGN
  • APLM
  • Stock Information
  • Founded
  • NKGN 2017
  • APLM 2016
  • Country
  • NKGN United States
  • APLM United States
  • Employees
  • NKGN N/A
  • APLM N/A
  • Industry
  • NKGN Biotechnology: Biological Products (No Diagnostic Substances)
  • APLM Blank Checks
  • Sector
  • NKGN Health Care
  • APLM Finance
  • Exchange
  • NKGN Nasdaq
  • APLM Nasdaq
  • Market Cap
  • NKGN 14.1M
  • APLM 15.6M
  • IPO Year
  • NKGN N/A
  • APLM N/A
  • Fundamental
  • Price
  • NKGN $0.65
  • APLM $9.75
  • Analyst Decision
  • NKGN
  • APLM Strong Buy
  • Analyst Count
  • NKGN 0
  • APLM 2
  • Target Price
  • NKGN N/A
  • APLM $425.00
  • AVG Volume (30 Days)
  • NKGN 573.8K
  • APLM 107.4K
  • Earning Date
  • NKGN 12-31-2024
  • APLM 02-15-2025
  • Dividend Yield
  • NKGN N/A
  • APLM N/A
  • EPS Growth
  • NKGN N/A
  • APLM N/A
  • EPS
  • NKGN N/A
  • APLM N/A
  • Revenue
  • NKGN N/A
  • APLM $2,101,000.00
  • Revenue This Year
  • NKGN N/A
  • APLM N/A
  • Revenue Next Year
  • NKGN N/A
  • APLM N/A
  • P/E Ratio
  • NKGN N/A
  • APLM N/A
  • Revenue Growth
  • NKGN N/A
  • APLM 70.54
  • 52 Week Low
  • NKGN $0.20
  • APLM $6.50
  • 52 Week High
  • NKGN $4.06
  • APLM $105.00
  • Technical
  • Relative Strength Index (RSI)
  • NKGN 65.93
  • APLM 50.39
  • Support Level
  • NKGN $0.45
  • APLM $7.23
  • Resistance Level
  • NKGN $0.62
  • APLM $8.88
  • Average True Range (ATR)
  • NKGN 0.08
  • APLM 1.37
  • MACD
  • NKGN 0.01
  • APLM 0.21
  • Stochastic Oscillator
  • NKGN 70.95
  • APLM 57.91

About NKGN NKGen Biotech Inc.

NKGen Biotech Inc is a biotechnology company developing cell therapies for neurodegenerative and oncological diseases based on activated NK cells. NK cells are part of the human innate immune response system that can selectively identify and destroy abnormal or diseased cells. Its product candidates are based on a proprietary manufacturing and cryopreservation process that produces SuperNKTM (SNK) cells that have shown increased activity as compared to the starting population of NK cells, based on the results of in vitro experiments performed by NKMAX, as defined by parameters such as cytotoxicity, cytokine production and activating receptor expression. SNK cells can be produced in large quantities and cryopreserved while maintaining high levels of cytotoxicity.

About APLM Apollomics Inc.

Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.

Share on Social Networks: